La cadena de opciones muestra datos clave de las opciones de acciones de ArriVent BioPharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para ArriVent BioPharma..

ArriVent BioPharma (NASDAQ:AVBP) Bolsa, Cadena de Opciones

ARRIVENT BIOPHARMA INC

ArriVent BioPharma

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Explora los movimientos más destacados del pre-mercado, incluyendo el aumento del 23% en Logility y más sorpresas.

Acciones de Logility Supply Chain (LGTY) suben un 23%; 20 acciones que se mueven en el premercado de EE.UU.

ArriVent BioPharma Inc

Management

Press Releases

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Earnings

ArriVent BioPharma Reports First Quarter 2025 Financial Results

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

General

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

Astria Therapeutics

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

CareDx

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Emergent BioSolutions

Erasca

Geron

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gyre Therapeutics

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Lexeo Therapeutics

MeiraGTx Hldgs

Myriad Genetics

Nanobiotix

Prime Medicine

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

RAPT Therapeutics

Replimune Group

Regenxbio

Rezolute

ARS Pharmaceuticals

Savara

Tyra Biosciences

Valneva

Vir Biotechnology

HC Wainwright & Co.

Citigroup

Goldman Sachs

Clear Street

Oppenheimer

Comments

ArriVent BioPharma

ArriVent BioPharma (AVBP) Opciones

ArriVent BioPharma (NASDAQ:AVBP) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL